Skip to main content

Advertisement

SpringerLink
Log in

Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson’s disease symptoms by regulating brain amyloid β1–42 level

  • Published:
Molecular and Cellular Biochemistry Aims and scope Submit manuscript

Abstract

Repetitive transcranial magnetic stimulation (rTMS) is a technique protecting neurons against diverse neurodegenerative disorders by delivering magnetic stimuli into the brain through the intact scalp. In the current study, the protection effect of rTMS on Parkinson’s disease (PD) and the associated mechanism driving the treatment were explored. The PD symptoms were induced using 6-OHDA in mice, and the effect of rTMS of two frequencies (1 Hz and 10 Hz) on the cognitive behaviors and neuron viability was detected. Afterwards, the level of Aβ1–42 and activity of MKK7-ERK-Fos-APP axis under the administration of rTMS were recorded as well. The intracranial injection of 6-OHDA impaired the cognitive behaviors of the mice in the test of Morris water maze as well as reducing the viability and number of neurons in PD mice. After the treatment of rTMS of both frequencies, the cognitive function of mice was improved and the neuron viability and number were restored in mice brain tissues. The administration of rTMS also increased the cerebrospinal fluid (CSF) level of Aβ1–42 in PD mice, which was accompanied by the suppressed levels of p-MKK7, p-ERK1/2, p–c-Fos, and APP. Moreover, the effect of rTMS on mice nerve system was all exerted in a frequency-dependent manner. In conclusion, the findings outlined in the current study affirmed the protection effect of rTMS against PD. The anti-PD function of rTMS was associated with the suppression of MKK7-ERK-Fos-APP axis, which subsequently resulted in the increased CSF Aβ1–42 level and decreased brain Aβ1–42 level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Driver JA, Logroscino G, Gaziano JM, Kurth T (2009) Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 72(5):432–438. https://doi.org/10.1212/01.wnl.0000341769.50075.bb

    Article  PubMed  PubMed Central  Google Scholar 

  2. Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, Bennett DA (2012) Nigral pathology and parkinsonian signs in elders without Parkinson’s disease. Ann Neurol 71(2):258–266

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lees AJ, Hardy J, Revesz T (2004) Parkinson’s disease. Lancet 363(Suppl):1783–1793

    Google Scholar 

  4. Marras C, Lang A (2013) Parkinson’s disease subtypes: lost in translation? J Neurol Neurosur Ps 84(4):409–415. https://doi.org/10.1136/jnnp-2012-303455

    Article  Google Scholar 

  5. van Dijk KD, Teunissen CE, Drukarch B, Jimenez CR, Groenewegen HJ, Berendse HW, van de Berg WD (2010) Diagnostic cerebrospinal fluid biomarkers for Parkinson’s disease: a pathogenetically based approach. Neurobiol Dis 39(3):229–241. https://doi.org/10.1016/j.nbd.2010.04.020

    Article  CAS  PubMed  Google Scholar 

  6. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D (2010) Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 9(11):1044–1045

    Article  Google Scholar 

  7. Nyhlén J, Constantinescu R, Zetterberg H (2010) Problems associated with fluid biomarkers for Parkinson’s disease. Biomarkers Med 4(5):671–681

    Article  Google Scholar 

  8. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, Calabresi P (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 9(3):131–140

    Article  CAS  PubMed  Google Scholar 

  9. Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB (2015) Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson’s disease. Movement Disord 30(7):936–944

    Article  CAS  PubMed  Google Scholar 

  10. Zetterberg H, Lunn MP, Herukka SK (2012) Clinical use of cerebrospinal fluid biomarkers in Alzheimer’s disease. Biomarkers Med 6(4):371–376

    Article  CAS  Google Scholar 

  11. Postina R (2008) A closer look at alpha-secretase. Curr Alzheimer Res 5(2):179–186

    Article  CAS  PubMed  Google Scholar 

  12. Deuss M, Reiss K, Hartmann D (2008) Part-time alpha-secretases: the functional biology of ADAM 9, 10 and 17. Curr Alzheimer Res 5:2

    Article  Google Scholar 

  13. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest 113(10):1456

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Colciaghi F, Borroni B, Pastorino L, Marcello E, Zimmermann M, Cattabeni F, Padovani A, Di LM (2002) [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mo Med 8(2):67

    Article  CAS  Google Scholar 

  15. Qin W, Ho L, Wang J, Peskind E, Pasinetti GM (2009) S100A7, a novel Alzheimer’s disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10. PLoS ONE 4(1):e4183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Zetterberg H, Andreasson U, Hansson O, Wu G, Sankaranarayanan S, Andersson ME, Buchhave P, Londos E, Umek RM, Minthon L (2008) Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch Neurol-Chicago 65(8):1102–1107

    Article  PubMed  Google Scholar 

  17. Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP, King E, Devanarayan V, Cook JJ, Simon AJ (2008) Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer’s subjects. Clin Biochem 41(12):986–996

    Article  CAS  PubMed  Google Scholar 

  18. Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H (2008) Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer’s disease. Brain 131(5):1252–1258

    Article  PubMed  Google Scholar 

  19. Sun X, Wang Y, Qing H, Christensen MA, Liu Y, Zhou W, Tong Y, Xiao C, Huang Y, Zhang S (2005) Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes. FASEB J 19(7):739–749

    Article  CAS  PubMed  Google Scholar 

  20. Stockley JH, O’Neill C (2007) The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer’s disease brain. Biochem Soc Trans 35(3):574–576

    Article  CAS  PubMed  Google Scholar 

  21. Zhang J (2002) aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev Cell 3(1):85–97

    Article  CAS  PubMed  Google Scholar 

  22. Baulac S, Lavoie MJ, Kimberly WT, Strahle J, Wolfe MS, Selkoe DJ, Xia W (2003) Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis 14(2):194–204

    Article  CAS  PubMed  Google Scholar 

  23. Kimberly WT, Lavoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ (2003) γ-secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and Pen-2. Proc Natl Acad Sci USA 100(11):6382–6387

    Article  CAS  PubMed  Google Scholar 

  24. Gersner R, Kravetz E, Feil J, Pell G, Zangen A (2011) Long-term effects of repetitive transcranial magnetic stimulation on markers for neuroplasticity: differential outcomes in anesthetized and awake animals. J Neurosci 31(20):7521–7526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wang HY, Crupi D, Liu J, Stucky A, Cruciata G, Di RA, Friedman E, Quartarone A, Ghilardi MF (2011) Repetitive transcranial magnetic stimulation enhances BDNF-TrkB signaling in both brain and lymphocyte. J Neurosci 31(30):11044–11054

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Miranda PC, Lomarev M, Hallett M (2006) Modeling the current distribution during transcranial direct current stimulation. Clin Neurophysio 117(7):1623–1629

    Article  Google Scholar 

  27. Fregni F, Simon D, Wu A, Pascual-Leone A (2005) Non-invasive brain stimulation for Parkinson’s disease: a systematic review and meta-analysis of the literature. J Neurol Neurosur Psychiatry 76(12):1614

    Article  CAS  Google Scholar 

  28. Tan T, Xie J, Liu T, Chen X, Zheng X, Tong Z, Tian X (2013) Low-frequency (1 Hz) repetitive transcranial magnetic stimulation (rTMS) reverses Aβ(1–42)-mediated memory deficits in rats. Exp Gerontol 48(8):786–794

    Article  PubMed  Google Scholar 

  29. Huang YA, Zhou B, Wernig M, Südhof TC (2017) ApoE2, ApoE3, and ApoE4 differentially stimulate app transcription and Aβ secretion. Cell 168(3):427

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Ridding MC, Rothwell JC (2007) Is there a future for therapeutic use of transcranial magnetic stimulation? Nat Rev Neurosci 8(7):559–567

    Article  CAS  PubMed  Google Scholar 

  31. Ni Z, Chen R (2015) Transcranial magnetic stimulation to understand pathophysiology and as potential treatment for neurodegenerative diseases. Transl Neurodegener 4(1):22

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Oscar AC (2008) Basic mechanisms of rTMS: implications in Parkinson’s disease. Int Arch Med 1(1):2

    Article  Google Scholar 

  33. Colaianna M, Tucci P, Zotti M, Morgese MG, Schiavone S, Govoni S, Cuomo V, Trabace L (2010) Soluble βamyloid1–42: a critical player in producing behavioural and biochemical changes evoking depressive-related state? Br J Pharmacol 159(8):1704

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M (2000) Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Mol Brain Res 76(2):347–354

    Article  CAS  PubMed  Google Scholar 

  35. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De CC, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B (2011) Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson’s disease and degenerative dementias. Mov Disord 26(8):1428–1435

    Article  PubMed  Google Scholar 

  36. Elahi B, Chen R (2010) Effect of transcranial magnetic stimulation on Parkinson motor function–systematic review of controlled clinical trials. Mov Disord 24(3):357–363

    Article  Google Scholar 

  37. Zanjani A, Zakzanis KK, Daskalakis ZJ, Chen R (2015) Repetitive transcranial magnetic stimulation of the primary motor cortex in the treatment of motor signs in Parkinson’s disease: a quantitative review of the literature. Mov Disord 30(6):750–758

    Article  PubMed  Google Scholar 

  38. Nielsen NS, Jacobsen C (1997) Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation. Neurology 48(5):1398–1403

    Article  Google Scholar 

  39. Wagleshukla A, Angel MJ, Zadikoff C, Enjati M, Gunraj C, Lang AE, Chen R (2007) Low-frequency repetitive transcranial magnetic stimulation for treatment of levodopa-induced dyskinesias. Neurology 68(9):704–705

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Author information

Authors and Affiliations

  1. Department of Rehabilitation, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang, 110004, People’s Republic of China

    Fang Ba, Yuxin Zhou, Jie Zhou & Xueyun Chen

Authors
  1. Fang Ba
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuxin Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xueyun Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xueyun Chen.

Ethics declarations

Conflict of interest

The authors disclose no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

11010_2019_3531_MOESM1_ESM.tif

Supplementary material 1 (TIFF 83 kb) Figure S1. Schematic diagram of the experiment schedule. 10-week old mice were intracranially injected with 2 μl 6-OHDA (4 μg/μl) and housed routinely for 2 weeks before rTMS treatment of 2 weeks.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ba, F., Zhou, Y., Zhou, J. et al. Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson’s disease symptoms by regulating brain amyloid β1–42 level. Mol Cell Biochem 458, 71–78 (2019). https://doi.org/10.1007/s11010-019-03531-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11010-019-03531-w

Keywords

Search

Navigation